Aleš Chodacki

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Chris Parker, Sten Nilsson, Daniel Heinrich et al. · New England Journal of Medicine · 2013 · 3.3K citations

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

Oliver Sartor, Robert L. Coleman, Sten Nilsson et al. · The Lancet Oncology · 2014 · 485 citations

Urology, Oncology, Medicine +8

A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer

Christopher Parker, S. Pascoe, Aleš Chodacki et al. · European Urology · 2012 · 183 citations

Ra 223, Radiation Medicine, Urology +7

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

Chris Parker, Daniel Heinrich, Joe M. O’Sullivan et al. · European Journal of Cancer · 2011 · 137 citations

Radiation Medicine, Urology, Radiation Therapy +8

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial

Christopher Parker, Robert E. Coleman, Oliver Sartor et al. · European Urology · 2017 · 103 citations · Full text